CD45 (LCA) (2B11 & PD7/26) Mouse Monoclonal Antibody
Specialties: Hematopathology
Anti-CD45 (anti-leukocyte common antigen) is routinely used to aid the differential diagnosis of undifferentiated neoplasms, whenever malignant lymphoma is suspected by the morphological or clinical data. It is a highly specific antibody; therefore a positive result is highly indicative of hematolymphoid origin. Certain types of hematolymphoid neoplasms may lack CD45 (Hodgkin lymphoma, some T-cell lymphomas, and some leukemias) so its absence does not rule out a hematolymphoid tumor. This antibody is expressed almost exclusively by cells of hematopoietic lineage and is present in most benign and malignant lymphocytes as well as plasma cell precursors.1-8
- Mason DY. A new look at lymphoma immunohistology. Am J Pathol. 1987; 128:1-4.
- Hall PA, et al. Paraffin section immunohistochemistry. I. Non-Hodgkin's lymphoma. Histopathology. 1988; 13:149-60.
- Kurtin PJ, et al.  Leukocyte common antigen--a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization. Hum Pathol. 1985; 16:353-65.
- Maluf HM, et al. Fibroma and giant cell tumor of tendon sheath: a comparative histological and immunohistological study. Mod Pathol. 1995; 8:155-9.
- Caballero T, et al. Intraepithelial and lamina propria leucocyte subsets in inflammatory bowel disease: an immunohistochemical study of colon and rectal biopsy specimens. J Clin Pathol. 1995; 48:743-8.
- Vasef MA, et al. Immunophenotype of Reed-Sternberg and Hodgkin's cells in sequential biopsy specimens of Hodgkin's disease: a paraffin-section immunohistochemical study using the heat-induced epitope retrieval method. Am J Clin Pathol. 1997; 108:54-9.
- Saxena, A et al. A combination of abnormal immunoarchitecture and reproducible clonal bands identifies the biologic nature of cutaneous B-cell infiltrates. Am J Clin Pathol 1999; 112:495-512.
- Kraus, MD et al. Lymphocyte predominance Hodgkin's disease: the use of bcl-6 and CD57 in diagnosis and differential diagnosis. Am J Surg Pathol 2000; 24:1068-78.
Specifications
- Reactivity: paraffin
- Control: Tonsil, Lymph Node (Membranous); Lymphoma (Membranous)
- Dilution Range: 1:100-1:500 *
Package Inserts
IFU
- IVD Rev. 6.0 (CMC14529060)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 25.0 mL predilute ready-to-use | 145M-90 |
| 0.1 mL concentrate | 145M-94 |
| 0.5 mL concentrate | 145M-95 |
| 1.0 mL concentrate | 145M-96 |
| 1.0 mL predilute ready-to-use | 145M-97 |
| 7.0 mL predilute ready-to-use | 145M-98 |
For in vitro diagnostic (IVD) use in Canada
| 25.0 mL predilute ready-to-use | 145M-90 |
| 0.1 mL concentrate | 145M-94 |
| 0.5 mL concentrate | 145M-95 |
| 1.0 mL concentrate | 145M-96 |
| 1.0 mL predilute ready-to-use | 145M-97 |
| 7.0 mL predilute ready-to-use | 145M-98 |
For in vitro diagnostic (IVD) use in Europe
| 25.0 mL predilute ready-to-use | 145M-90 |
| 0.1 mL concentrate | 145M-94 |
| 0.5 mL concentrate | 145M-95 |
| 1.0 mL concentrate | 145M-96 |
| 1.0 mL predilute ready-to-use | 145M-97 |
| 7.0 mL predilute ready-to-use | 145M-98 |
For research use only (RUO) in Japan
| 25.0 mL predilute ready-to-use (RUO) | 145M-90-RUO |
| 0.1 mL concentrate (RUO) | 145M-94-RUO |
| 0.5 mL concentrate (RUO) | 145M-95-RUO |
| 1.0 mL concentrate (RUO) | 145M-96-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 145M-97-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 145M-98-RUO |
To request information on this product in additional countries, please click the button below.
